| Market Capitalization (Millions $) |
175 |
| Shares
Outstanding (Millions) |
19 |
| Employees |
76 |
| Revenues (TTM) (Millions $) |
64 |
| Net Income (TTM) (Millions $) |
-3 |
| Cash Flow (TTM) (Millions $) |
29 |
| Capital Exp. (TTM) (Millions $) |
1 |
Business Description
Xilio Therapeutics Inc is a biotechnology company that specializes in the development of tumor-selective immuno-oncology therapies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts, with additional offices in Boston and San Francisco.
Xilio Therapeutics' revolutionary approach is to develop therapies that target cancer cells directly, while sparing normal cells. The company believes that by doing so, they can create more effective therapies that minimize side-effects experienced by patients.
The company's proprietary platform is based on Tumor Selective Immuno-Transfer (TSIT), which is a technology that enables the creation of potent, tumor-selective immunotherapies. TSIT is designed to target multiple mechanisms of immune evasion, which is a major obstacle in the treatment of cancer.
Xilio Therapeutics' lead candidate, XTX202, is a tumor-selective T cell therapy designed to attack solid tumors. XTX202 is being evaluated in preclinical models, and the company anticipates initiating clinical trials in the near future. XTX202 has shown significant efficacy in preclinical models, and the company is hopeful that it will translate into positive clinical results.
The company has also developed a pipeline of additional candidates targeting other types of cancer, including hematologic malignancies and solid tumors. Xilio Therapeutics is led by a team of industry veterans, including CEO Rene Russo and CMO Michel Sadelain, who have a wealth of experience in the development and commercialization of immunotherapies.
Xilio Therapeutics has raised over $100 million in funding to date, including a $95 million Series C financing round in October 2020. The company has partnerships with several leading biotech and pharmaceutical companies, including Boehringer Ingelheim, Roche, and Takeda.
Overall, Xilio Therapeutics Inc represents a promising and innovative approach to developing cancer treatments that could potentially revolutionize the field of immuno-oncology.
Company Address: 828 Winter Street Waltham 2451 MA
Company Phone Number: 524-2466 Stock Exchange / Ticker: NASDAQ XLO
|
2.68% 